Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Advanced Blood Test Detects and Analyzes Circulating Tumor Cells

By Labmedica International staff writers
Posted on 13 Feb 2012
Print article
An advanced blood test detects and analyzes circulating tumor cells (CTCs) from cancer patients.

The new test, called high definition CTC (HD-CTC), labels cells in a patient's blood sample in a way that distinguishes possible CTCs from ordinary red and white blood cells. A digital microscope and an image-processing algorithm are used to isolate the suspect cells with sizes and shapes (morphologies) unlike those of healthy cells. A pathologist can examine the images of the suspected CTCs to eliminate false positives and note their morphologies.

Scientists from The Scripps Research Institute (TSRI; La Jolla, CA, USA), Scripps Health, and collaborating cancer physicians successfully demonstrated the effectiveness of the blood test. Five new studies resulted from the collaboration and demonstrated the new test's accuracy and effectiveness for a number of different cancer types. The studies also began to explore the utility of the technology for diagnosing and monitoring patients and improving cancer research in the lab.

"It is a next-generation technology," said Scripps' Associate Prof. Peter Kuhn, PhD, senior investigator of the new studies and primary inventor of the high-definition blood test. "It significantly boosts our ability to monitor, predict, and understand cancer progression, including metastasis, which is the major cause of death for cancer patients."

Whereas other tests for CTCs typically use enrichment steps in which suspected CTCs are concentrated--methods that can inadvertently exclude some types of CTCs--the new studies show HD-CTC works well as a no-cell-left-behind process and enables a more complete analysis.

Prof. Kuhn emphasized that the basic setup can be easily modified with different cell-labeling and image-processing techniques. He and his colleagues will study the use of HD-CTC as a potential screening test and develop it further for use in clinical monitoring and cancer research. Prof. Kuhn has founded a San Diego-based biotechnology company, Epic Sciences, Inc. (CA, USA) to develop HD-CTC commercially for companion diagnostic products in personalized cancer care.

The studies were published in the February 2012 edition of the journal Physical Biology.

Related Links:
The Scripps Research Institute
Epic Sciences



Print article
MERIDIAN BIOSCIENCE

Channels

Genetic Tests

view channel

Patterns of MicroRNA Expression Distinguish Patients with Asthma and Allergic Rhinitis

Subsets of circulating micro RNAs (miRNAs) are uniquely expressed in asthmatic patients and in patients with allergic rhinitis (AR) and have potential for use as noninvasive biomarkers to diagnose and characterize these diseases. MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression... Read more

Lab Tech.

view channel
Image: The cobas IT 1000 connectivity system (Photo courtesy of Roche).

New Application Connects Point-of-Care Coordinators via Tablet or Smartphone

A new mobile application has been released that allows point-of-care coordinators (POCCs) and laboratory supervisors to control operations from any location. Modern-day laboratories face modern-day challenges.... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.